Eli Lilly continues to dominate the obesity market with Zepbound and Orforglipron, leading JPMorgan to see it as a top pick ...

A survey by PSG has found that the pressure to control drug costs is leading some payers to look into unbundling pharmacy ...

Hims & Hers Health is betting that the cash-pay market for weight-loss drugs will drive up customer demand although some ...

“With the semaglutide shortage declared over, Hims now has to transition its model to generate growth from other products ...

Some Blue Cross and Blue Shield insurers dipped their toes into expanding coverage for blockbuster weight-loss drugs, then ...

Fifteen Connecticut companies made the 2025 Fortune 500 list of the largest U.S. corporations, which was announced Monday-- a sign of stability in the state's corporate sector. Bloomfield- ...

While employers aren’t yet reimbursing weight loss drugs en masse, significantly reduced net costs could affect their future ...

Novo Nordisk is rapidly ceding market share to Eli Lilly. And the paradigm shift is showing up in Novo Nordisk stock.

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Drugmakers are offering the blockbuster medications at steep discounts to people willing to pay out of pocket.

Earlier this month, CVS Caremark announced that it will now cover Wegovy under its pharmacy benefit plans — but it will no longer cover Zepbound. A study published in the New England Journal of ...